Integrated DNA Technologies Executive and Leadership Team

Maz Mohadjer, the Chief Executive Officer at Integrated DNA Technologies, directs the overarching corporate strategy for custom nucleic acid manufacturing. Mohadjer oversees the alignment of research initiatives with the evolving needs of the biotechnology and pharmaceutical sectors. By prioritizing high-quality production standards, the Chief Executive Officer ensures that academic and clinical partners receive precise genomic tools. This leadership role involves managing complex supply chains to maintain market leadership in the life sciences industry. Maz Mohadjer drives organizational growth by fostering innovation in synthetic biology applications. Through rigorous oversight of internal processes, the Chief Executive Officer maintains operational excellence across all manufacturing facilities. The strategic vision provided by Mohadjer supports the long-term expansion of the company into emerging diagnostic markets. Ultimately, the Chief Executive Officer secures the competitive position of the firm by delivering reliable, high-performance nucleic acid products to a diverse global client base.

Alfonso Avila, the Group Chief Executive Officer at Integrated DNA Technologies, manages the broad operational scale of the organization across international territories. Avila coordinates the integration of regional manufacturing units to ensure consistent product delivery for clinical diagnostics and pharmaceutical development. The Group Chief Executive Officer architects scalable workflows that support the rapid production of custom nucleic acids. By optimizing cross-functional collaboration, Alfonso Avila enhances the efficiency of global distribution networks. This leadership role requires constant monitoring of market trends to adapt manufacturing capabilities to new research demands. Avila drives the implementation of advanced quality control systems to meet stringent industry regulations. Through the management of large-scale operational projects, the Group Chief Executive Officer sustains the company's reputation for technical precision. Ultimately, Avila strengthens the global footprint of the firm by aligning regional output with the core mission of supporting life sciences innovation.

Alan M, the Chief Financial Officer at Integrated DNA Technologies, directs the fiscal strategy and capital allocation for the manufacturing of custom nucleic acids. M oversees the financial health of the organization, ensuring resources support critical research and development projects in the pharmaceutical sector. The Chief Financial Officer manages budgetary planning to facilitate the expansion of production capacity for clinical diagnostics. By analyzing market data, Alan M provides the insights necessary for sustainable growth and long-term investment. This leadership role involves maintaining transparent reporting standards for the board and stakeholders. M drives cost-efficiency initiatives across all departments to maximize operational margins. Through the oversight of financial risk, the Chief Financial Officer protects the company's assets while funding innovation in life sciences. Ultimately, M secures the financial stability required to maintain the firm's status as a premier supplier of genomic products to the global research community.

Chuen-Der Lien, the Chief Technology Officer at Integrated DNA Technologies, architects the technical infrastructure required for the synthesis of high-quality nucleic acids. Lien oversees the development of proprietary manufacturing platforms that serve the biotechnology and academic research industries. The Chief Technology Officer drives innovation in molecular biology tools to improve the accuracy and speed of genomic products. By managing the research and development pipeline, Chuen-Der Lien ensures the company remains at the forefront of synthetic biology. This leadership role involves collaborating with engineering teams to automate production processes for clinical diagnostics. Lien directs the implementation of cutting-edge laboratory technologies to enhance product performance. Through the continuous improvement of technical standards, the Chief Technology Officer supports the company's commitment to scientific excellence. Ultimately, Lien advances the firm's technological capabilities, enabling researchers to achieve breakthroughs in pharmaceutical development and complex diagnostic applications.